Stefan L Kavanagh - JoVE Visualize

Showing results (1-10 of 5) with videos related to

Pageof 1

Sort By:

Drug Discovery Today|November 26, 2013

Reducing attrition in drug development: smart loading preclinical safety assessmentRuth A Roberts, Stefan L Kavanagh, Howard R Mellor, et al.

Journal of Medicinal Chemistry|December 16, 2022

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for OncologyFrederick W Goldberg, Jason G Kettle, Gillian M Lamont, et al.

ACS Medicinal Chemistry Letters|December 20, 2023

Discovery of a Novel Benzodiazepine Series of Cbl-b Inhibitors for the Enhancement of Antitumor ImmunityJeffrey A Boerth, Alex J Chinn, Marianne Schimpl, et al.

Journal of Medicinal Chemistry|January 16, 2024

Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b InhibitorsAdelphe M Mfuh, Jeffrey A Boerth, Gayathri Bommakanti, et al.

Journal of Medicinal Chemistry|February 2, 2023

Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-AntagonistsJames S Scott, Darren Stead, Bernard Barlaam, et al.

Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:

Pageof 1

Drug Discovery Today|November 26, 2013

Reducing attrition in drug development: smart loading preclinical safety assessmentRuth A Roberts, Stefan L Kavanagh, Howard R Mellor, et al.

Journal of Medicinal Chemistry|December 16, 2022

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for OncologyFrederick W Goldberg, Jason G Kettle, Gillian M Lamont, et al.

ACS Medicinal Chemistry Letters|December 20, 2023

Discovery of a Novel Benzodiazepine Series of Cbl-b Inhibitors for the Enhancement of Antitumor ImmunityJeffrey A Boerth, Alex J Chinn, Marianne Schimpl, et al.

Journal of Medicinal Chemistry|January 16, 2024

Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b InhibitorsAdelphe M Mfuh, Jeffrey A Boerth, Gayathri Bommakanti, et al.

Journal of Medicinal Chemistry|February 2, 2023

Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-AntagonistsJames S Scott, Darren Stead, Bernard Barlaam, et al.

Pageof 1